Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

860629P

Avanti

C24:1 Dihydroceramide (d18:0/24:1(15Z))

Avanti Research™ - A Croda Brand 860629P, powder

Sinónimos:

N-nervonoyl-D-erythro-sphinganine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C42H83NO3
Número de CAS:
352518-80-0
Peso molecular:
650.11
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 5 mg (860629P-5mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 860629P

lipid type

sphingolipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

OC[C@]([H])(NC(CCCCCCCCCCCCC/C=C\CCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC

InChI

1S/C42H83NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h17-18,40-41,44-45H,3-16,19-39H2,1-2H3,(H,43,46)/b18-17-/t40-,41+/m0/s1

InChI key

YUULKFVZRXQHPM-ATHUGRIKSA-N

Categorías relacionadas

Application

C24:1 Dihydroceramide has been used as a standard in quadrupole time-of-flight (Q-TOF) mass spectrometry for the measurement of sphingolipid metabolites in adipose tissue. It has also been used a standard in diacylglycerol kinase (DGK) assay to quantify dihydroceramides in CLN9-deficient cells.

Biochem/physiol Actions

C24:1 Dihydroceramide is a synthetic dihydroceramide. Dihydroceramides are reduced to ceramides by the enzyme dihydroceramide desaturase. Elevated levels of serum 24:1 DHC has been observed in patients with history of hepatocellular carcinoma (HCC) pre-orthopic liver transplantation (OLT), compared to patients with no prior HCC. Therefore, 24:1 DHC can be used as a HCC biomarker in post-OLT patients.

Packaging

5 mL Amber Glass Screw Cap Vial (860629P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

also commonly purchased with this product

Referencia del producto
Descripción
Precios

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

C22: 0-and C24: 0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines
Holliday Jr, et al.
PLoS ONE, 8(9) (2013)
The CLN9 protein, a regulator of dihydroceramide synthase
Schulz A, et al.
The Journal of Biological Chemistry, 281(5), 2784-2794 (2006)
Michael W Holliday et al.
PloS one, 8(9), e74768-e74768 (2013-09-17)
We previously reported that fenretinide (4-HPR) was cytotoxic to acute lymphoblastic leukemia (ALL) cell lines in vitro in association with increased levels of de novo synthesized dihydroceramides, the immediate precursors of ceramides. However, the cytotoxic potentials of native dihydroceramides have
C22: 0-and C24: 0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines
Holliday Jr, et al.
Testing, 8(9) (2013)
Angela Schulz et al.
The Journal of biological chemistry, 281(5), 2784-2794 (2005-11-24)
A new variant of a group of pediatric neurodegenerative diseases known as neuronal ceroid lipofuscinosis (NCL) or Batten disease has been identified. It is termed CLN9-deficient. CLN9-deficient fibroblasts have a distinctive phenotype of rapid growth and increased apoptosis and diminished
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico